Search
With an aging population that is increasingly choosing to stay in the workforce past the standard retirement age, new issues are emerging in the field of workers’ compensation and workplace medical management. In light of these trends, myMatrixx has published a report on this topic, titled “Preparing...
After alerts that it issued last fall, the FDA decided on April 1, 2020, to ask all manufacturers of products containing ranitidine to remove their products from the market. An oral histamine-2 (H2) blocker, ranitidine was available both with and without a prescription. Sold under the brand-name,...
Our “Workers’ Compensation Pharmaceuticals: Prior Authorization and High Dollar Rejections Guide” and our “Brand to Generic Reference Guide: Workers’ Compensation Pharmaceuticals” are two of the most widely used reference materials at myMatrixx. Due to the constantly changing nature...
As specialty drugs continue to become the standard treatment for many rare and chronic conditions, these newer and complex medications are also driving costs upward. In fact, Information Medical Statistics (IMS) Health estimates that specialty net spending in the United States rose from 24.7% in 2008...
myMatrixx President Mike Cirillo was recently quoted in a piece for Risk & Insurance Magazine covering the major forces that will be shaping the workers’ comp field in the next decade. The article focuses on a new book by Workers’ Compensation Research Institute (WCRI) founder and Sedgewick...
Ahead of the release of our 2019 Drug Trend Report, myMatrixx will once again be holding a live webcast to review and analyze key findings from the study. Hosted by myMatrixx President Mike Cirillo , the event will be held on Thursday, April 23rd, from 2PM to 3PM EST. Joining Mike will be Phil Walls...
myMatrixx is closely monitoring the 2019 Novel Coronavirus (COVID-19) and our top priority is the safety and service of our customers, clients, employees and partners. “The spread of the novel coronavirus, COVID-19, is raising concerns around the world. People want to know how to stay safe, how...
In a recent update , we shared that myMatrixx Clinical Account Executive Shanea McKinney has had multiple speaking proposals accepted to RIMS, the risk management society’s Professional Exchange of Risk Knowledge, or PERK, program. Well, we’re pleased to announce that two separate RIMS chapters...
myMatrixx is committed to helping our clients succeed.
Over the coming months, members of the myMatrixx clinical team will be delivering educational presentations for the CEU Institute, a national continuing education accreditation management organization. myMatrixx Chief Clinical Officer Phil Walls and Clinical Account Executive Shanea McKinney will...